Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH5030 in Advanced HER2-positive Solid Tumors
NCT05245058Phase 1Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sph5030 in HER2-positive solid tumor (HER2+), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Dose-limiting toxicity at 24 days, Maximum tolerated dose at 24 days and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
sph5030
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT05245058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245058.